Novel Beta Lactam Antibiotics for the Treatment of Multidrug-Resistant Gram-Negative Infections in Children: A Narrative Review

被引：10

作者：

Venuti, Francesco ^{[1
]}

Romani, Lorenza ^{[2
]}

De Luca, Maia ^{[2
]}

Tripiciano, Costanza ^{[2
]}

Palma, Paolo ^{[3
,4
]}

Chiriaco, Maria ^{[5
]}

Finocchi, Andrea ^{[4
,5
]}

Lancella, Laura ^{[2
]}

机构：

[1] Univ Torino, Amedeo Savoia Hosp, Dept Med Sci, Unit Infect Dis, I-10149 Turin, Italy

[2] Bambino Gesu Pediat Hosp, Infect Dis Unit, IRCCS, I-00165 Rome, Italy

[3] Bambino Gesu Pediat Hosp, Unit Clin Immunol & Vaccinol, IRCCS, I-00165 Rome, Italy

[4] Univ Roma Tor Vergata, Dept Syst Med, I-00133 Rome, Italy

[5] Bambino Gesu Pediat Hosp, Res Unit Primary Immunodeficiencies, IRCCS, I-00165 Rome, Italy

来源：

MICROORGANISMS | 2023年 / 11卷 / 07期

关键词：

children; pediatric; multidrug resistant; Gram-negative bacteria; infections; ceftolozane; tazobactam; ceftazidime; avibactam; meropenem; vaborbactam; imipenem; relebactam; cefiderocol; URINARY-TRACT-INFECTIONS; CEFTAZIDIME-AVIBACTAM RESISTANCE; CYSTIC-FIBROSIS PATIENT; IN-VITRO SUSCEPTIBILITY; BLOOD-STREAM INFECTION; PSEUDOMONAS-AERUGINOSA; CEFTOLOZANE-TAZOBACTAM; KLEBSIELLA-PNEUMONIAE; EXTENDED-SPECTRUM; INTRAABDOMINAL INFECTIONS;

D O I：

10.3390/microorganisms11071798

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Infections due to carbapenem-resistant Enterobacterales (CRE) are increasingly prevalent in children and are associated with poor clinical outcomes, especially in critically ill patients. Novel beta lactam antibiotics, including ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, imipenem-cilastatin-relebactam, and cefiderocol, have been released in recent years to face the emerging challenge of multidrug-resistant (MDR) Gram-negative bacteria. Nonetheless, several novel agents lack pediatric indications approved by the Food and Drug Administration (FDA) and the European Medicine Agency (EMA), leading to uncertain pediatric-specific treatment strategies and uncertain dosing regimens in the pediatric population. In this narrative review we have summarized the available clinical and pharmacological data, current limitations and future prospects of novel beta lactam antibiotics in the pediatric population.

引用

页数：22

共 155 条

[1] Use of Ceftolozane/Tazobactam in the Treatment of Multidrug-resistant Pseudomonas aeruginosa Bloodstream Infection in a Pediatric Leukemia Patient [J].

Aitken, Samuel L. ;

Kontoyiannis, Dimitrios P. ;

DePombo, April M. ;

Bhatti, Micah M. ;

Tverdek, Frank P. ;

Gettys, Suzanne C. ;

Nicolau, David P. ;

Nunez, Cesar A. .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2016, 35 (09) :1040-1042

[2] Long-Term Compassionate Use of Cefiderocol To Treat Chronic Osteomyelitis Caused by Extensively Drug-Resistant Pseudomonas aeruginosa and Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae in a Pediatric Patient [J].

Alamarat, Zain, I ;

Babic, Jessica ;

Tran, Truc T. ;

Wootton, Susan H. ;

Dinh, An Q. ;

Miller, William R. ;

Hanson, Blake ;

Wanger, Audrey ;

Gary, Joshua L. ;

Arias, Cesar A. ;

Perez, Norma .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (04)

[3] Ceftazidime-avibactam for the Treatment of Multidrug-resistant Pseudomonas aeruginosa Central Nervous System Infection in Pediatric Patient: A Case Report [J].

Almangour, Thamer A. ;

Alsubaie, Sarah ;

Ghonem, Leen ;

Almohaini, Hissah A. ;

Bakheet, Hind Mohammed ;

Altweijri, Ikhlass .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2022, 41 (05) :436-438

[4] Ceftolozane/Tazobactam in Neonates and Young Infants: The Challenges of Collecting Pharmacokinetics and Safety Data in This Vulnerable Patient Population [J].

Ang, Jocelyn Y. ;

Arrieta, Antonio ;

Bradley, John S. ;

Zhang, Zufei ;

Yu, Brian ;

Rizk, Matthew L. ;

Johnson, Matthew G. ;

Rhee, Elizabeth G. .

AMERICAN JOURNAL OF PERINATOLOGY, 2021, 38 (08) :804-809

[5] Multidrug-Resistant Pseudomonas aeruginosa Infection in a Child with Cystic Fibrosis [J].

Ang, Jocelyn Y. ;

Abdel-Haq, Nahed ;

Zhu, Frank ;

Thabit, Abrar K. ;

Nicolau, David P. ;

Satlin, Michael J. ;

van Duin, David .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (10) :5627-5630

[6]

[Anonymous], 2015, Rapid risk assessment. Zika virus epidemic in the Americas: potential association with microcephaly and Guillain-Barre syndrome

[7] Plasma pharmacokinetics of ceftolozane/tazobactam in pediatric patients with cystic fibrosis [J].

Arrieta, Antonio C. ;

Ang, Jocelyn Y. ;

Zhang, Zufei ;

Larson, Kajal B. ;

Yu, Brian ;

Johnson, Matthew G. ;

Rhee, Elizabeth G. ;

Feng, Ed H. ;

Rizk, Matthew L. .

PEDIATRIC PULMONOLOGY, 2020, 55 (08) :2025-2032

[8] In Vitro Activity of Imipenem-Relebactam Alone or in Combination with Amikacin or Colistin against Pseudomonas aeruginosa [J].

Asempa, Tomefa E. ;

Nicolau, David P. ;

Kuti, Joseph L. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (09)

[9]

Barnes MD, 2018, ANTIMICROB AGENTS CH, V62, DOI [10.1128/AAC.02406-17, 10.1128/aac.02406-17]

[10] Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial [J].

Bassetti, Matteo ;

Echols, Roger ;

Matsunaga, Yuko ;

Ariyasu, Mari ;

Doi, Yohei ;

Ferrer, Ricard ;

Lodise, Thomas P. ;

Naas, Thierry ;

Niki, Yoshihito ;

Paterson, David L. ;

Portsmouth, Simon ;

Torre-Cisneros, Julian ;

Toyoizumi, Kiichiro ;

Wunderink, Richard G. ;

Nagata, Tsutae D. .

LANCET INFECTIOUS DISEASES, 2021, 21 (02) :226-240

← 1 2 3 4 5 6 7 8 9 10 →